SG11201912433YA - Pro-drug peptide with improved pharmaceutical properties - Google Patents

Pro-drug peptide with improved pharmaceutical properties

Info

Publication number
SG11201912433YA
SG11201912433YA SG11201912433YA SG11201912433YA SG11201912433YA SG 11201912433Y A SG11201912433Y A SG 11201912433YA SG 11201912433Y A SG11201912433Y A SG 11201912433YA SG 11201912433Y A SG11201912433Y A SG 11201912433YA SG 11201912433Y A SG11201912433Y A SG 11201912433YA
Authority
SG
Singapore
Prior art keywords
pro
pharmaceutical properties
improved pharmaceutical
drug peptide
peptide
Prior art date
Application number
SG11201912433YA
Other languages
English (en)
Inventor
Robert Zimmer
Gilles Guichard
Juliette Fremaux
Claire Venin
Sebastien Goudreau
Original Assignee
Ureka Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ureka Sarl filed Critical Ureka Sarl
Publication of SG11201912433YA publication Critical patent/SG11201912433YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201912433YA 2017-06-29 2018-06-29 Pro-drug peptide with improved pharmaceutical properties SG11201912433YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762526678P 2017-06-29 2017-06-29
PCT/IB2018/000838 WO2019002945A2 (en) 2017-06-29 2018-06-29 PEPTIDE PRO-MEDICINE HAVING IMPROVED PHARMACEUTICAL PROPERTIES

Publications (1)

Publication Number Publication Date
SG11201912433YA true SG11201912433YA (en) 2020-01-30

Family

ID=63684203

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912433YA SG11201912433YA (en) 2017-06-29 2018-06-29 Pro-drug peptide with improved pharmaceutical properties

Country Status (11)

Country Link
US (2) US10889627B2 (ja)
EP (1) EP3645558A2 (ja)
JP (1) JP7046990B2 (ja)
KR (1) KR102398777B1 (ja)
CN (1) CN111051338A (ja)
AU (2) AU2018293467B2 (ja)
BR (1) BR112019028134A2 (ja)
CA (1) CA3067674A1 (ja)
IL (1) IL271741A (ja)
SG (1) SG11201912433YA (ja)
WO (1) WO2019002945A2 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148317A1 (en) 2019-01-18 2020-07-23 Ureka Sarl Peptide-oligourea hybrid compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1992010576A1 (en) * 1990-12-13 1992-06-25 The Upjohn Company Fusion polypeptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
NZ506839A (en) * 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US8404637B2 (en) * 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
FR2900341B1 (fr) * 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
WO2008086086A2 (en) * 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
US8084597B2 (en) * 2007-11-15 2011-12-27 Molecular Kinetics Incorporated Artificial entropic bristle domain sequences and their use in recombinant protein production
US20110288001A1 (en) 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
EP2552952A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9259477B2 (en) * 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US9446096B2 (en) 2011-12-30 2016-09-20 Joslin Diabetes Center, Inc. Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
WO2013098408A1 (en) * 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
EP3406347A3 (en) 2012-02-27 2019-02-13 Amunix Operating Inc. Xten conjugate compositions and methods of making same
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ

Also Published As

Publication number Publication date
EP3645558A2 (en) 2020-05-06
AU2021200731B2 (en) 2022-10-27
AU2018293467A1 (en) 2020-02-06
US20190002519A1 (en) 2019-01-03
KR102398777B1 (ko) 2022-05-17
JP2020525478A (ja) 2020-08-27
CN111051338A (zh) 2020-04-21
CA3067674A1 (en) 2019-01-03
AU2021200731A1 (en) 2021-03-04
US10889627B2 (en) 2021-01-12
WO2019002945A3 (en) 2019-02-21
IL271741A (en) 2020-02-27
WO2019002945A2 (en) 2019-01-03
KR20200028402A (ko) 2020-03-16
BR112019028134A2 (pt) 2020-09-29
WO2019002945A8 (en) 2020-02-13
JP7046990B2 (ja) 2022-04-04
AU2018293467B2 (en) 2020-11-05
US20210122800A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL268920A (en) Peptide components
ZA201702537B (en) Peptides having anti-inflammatory properties
IL275298B1 (en) Mitochondria-targeted peptides
GB201600911D0 (en) Stabilized peptide derivatives
HK1248729A1 (zh) 細胞毒性hexim1肽和其用途
SG11202005653RA (en) Novel peptide
GB201607534D0 (en) Peptides
IL269239A (en) A pharmaceutical combination containing fonsimod
GB201703876D0 (en) Pharmaceutical combinations
GB201700557D0 (en) Novel peptides
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
GB201604468D0 (en) Peptides
IL271741A (en) Peptide meters drug with improved pharmaceutical properties
GB201713700D0 (en) Peptide conjugates
GB201612150D0 (en) Modified peptide
GB201607535D0 (en) Peptides
GB201600903D0 (en) Peptide derivaties
EP3697808C0 (en) NEUROPROTECTIVE PEPTIDE
EP3438120A4 (en) NEUROPROTECTIVE PEPTIDE
GB201715379D0 (en) Peptides
GB201715378D0 (en) Peptides
GB201711620D0 (en) Peptides
GB201707837D0 (en) Peptides
AU2017265V (en) OPSTAL 20 Leucothoe axillaris
EP3438119A4 (en) NEUROPROTECTIVE PEPTIDE